Advaxis Doses First Cervical Dysplasia Clinical Trial Patient
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has dosed the first patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia. The clinical trial is slated to be a multicenter, randomized, placebo controlled, blinded clinical trial …
Read more on Medical News Today
